Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 June 2021Website:
http://www.monterosatx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:24:25 GMTDividend
Analysts recommendations
Institutional Ownership
GLUE Latest News
Monte Rosa Therapeutics, Inc. ("Monte Rosa") announced the pricing of a public offering of its common stock and pre-funded warrants, with expected gross proceeds of approximately $100 million.
Monte Rosa Therapeutics (GLUE) passed our "Recent Price Strength" screen and may be an attractive option for investors seeking to capitalize on stocks showing momentum.
The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
What type of business is Monte Rosa Therapeutics?
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
What sector is Monte Rosa Therapeutics in?
Monte Rosa Therapeutics is in the Healthcare sector
What industry is Monte Rosa Therapeutics in?
Monte Rosa Therapeutics is in the Biotechnology industry
What country is Monte Rosa Therapeutics from?
Monte Rosa Therapeutics is headquartered in United States
When did Monte Rosa Therapeutics go public?
Monte Rosa Therapeutics initial public offering (IPO) was on 24 June 2021
What is Monte Rosa Therapeutics website?
https://www.monterosatx.com
Is Monte Rosa Therapeutics in the S&P 500?
No, Monte Rosa Therapeutics is not included in the S&P 500 index
Is Monte Rosa Therapeutics in the NASDAQ 100?
No, Monte Rosa Therapeutics is not included in the NASDAQ 100 index
Is Monte Rosa Therapeutics in the Dow Jones?
No, Monte Rosa Therapeutics is not included in the Dow Jones index
When does Monte Rosa Therapeutics report earnings?
The next expected earnings date for Monte Rosa Therapeutics is 09 August 2024